BridgeBio Pharma Inc
(NAS:BBIO)
$
26.02
-0.17 (-0.65%)
Market Cap: 4.89 Bil
Enterprise Value: 6.17 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 44/100 BridgeBio Pharma Inc at H C Wainwright Precision Oncology Conference (Virtual) Transcript
Oct 20, 2021 / 04:00PM GMT
Release Date Price:
$45.4
(-3.75%)
Robert Burns
H.C. Wainwright & Co., LLC - Analyst
For our next fireside chat, I'm joined by Dr. Eli Wallace, the Chief Scientific Officer of the oncology (technical difficulty) at BridgeBio Pharma. Eli, thank you for joining us today. I look forward to a lively discussion.
Eli Wallace
BridgeBio Pharma, Inc. - Chief Scientific Officer, Oncology
Thanks, Rob. Thanks for inviting me. I'm glad to participate.
Robert Burns
H.C. Wainwright & Co., LLC - Analyst
Awesome. So for those who may be new or unfamiliar to BridgeBio's oncology portfolio, just given the size of Bridge's portfolio, can you provide a brief high-level overview of the oncology portfolio at BridgeBio and its recently announced partnership with BMS?
Eli Wallace
BridgeBio Pharma, Inc. - Chief Scientific Officer, Oncology
Yes. Thanks, Rob. So on this slide, this shows our broad precision oncology pipeline that includes improved agent as well as research programs and some of those that have the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot